Photo Credit: istock.com/kuzmik_a
AT 48 Weeks, 98% of Patients with HIV and Initial Viremia on Long-Acting Art Achieved viral Suppression, Supporting Updated HIV Treatment Guidelines.
Single-Centen Analysis of Long-Acacting Antiretroviral Therapy (La-ART) for Patients with Hiv Found High Rates of Viral Suppression at 48 Weeks In Both Researchers Reported Their Findings in a Letter Published in Jama.
“At 48 Weeks, 98% (94/96; 95% CI, 93% -99%) of Patients with Initial Viremia Had Undetectable Viral Loads, Including Five Whoven Viral Suppression With Use of La-Art But Returned to Oral Art for ADVERSENCE Events and Mintained Viral Suppression at 48 Weeks, ”wrote corresponding Author Monica Gandhi, MD, MPHand Colleagues.
The Study Investigated Viral Suppression Rates for 370 Patients with Hiv Who Attended the Special Program of Long-Acacting Antiretrovirals To Stop Hiv Initiative at the Ward 86 HIV Clinic in San Francisco Between January 2021 and Sepmber 2024. RNA level ≥30 Copies/ml) at la-art initiation, and 241 did not.
To participate in the Program, Patients with Viremia Were Required to Commit to Monthly In-Person Visits. The Authors of the Research Letter Explained That If Viral Load Fell to Undetactable Levels After 3 Months, Injections Were Spaced Bimonthly. The Pharmacist Reviewed Each Patient’s Art History and Resistance, and A Pharmacy Technician Provided Patienteling. Patients Received Appointment Reminders But Could Drop in for Injections Within a Week of the Target Date.
For patients with viremia, the median viral load at la-art initiation was 45,600 copies/ml, and cd4+ Counts Were Less Than 200 Cells/mm3 in 50%. Patients Who Started La-Art With Viremia Had Higher Rates of Substance Use, Housing Instability, and Low CD4+ Counts.
The Study Found That Rates of Viral Suppression at 24 Weeks Were 97% in Patients with Initial Viremia and 99% in Patients Without Initial Viremia. AT 48 Weeks, 98% of Patients with Initial Viremia Had Achieved Viral Suppression Compreded with 99% of Patients Without Initial Viremia.
“In 2024, Data From the Program Were Cited in Modifications to the US Department of Health and Human Services and International Antiviral Society-Usa Hiv Treatment Guidelines to Recommend La-Art Among People with Hiv with Viremia and Adherence Challenges,” The Authors Wrote. “These Comparison Data Further Bolster Changes to Hiv Treatment Guidelines.”
